PRICE 2 EARNINGS

Price to Earnings of Samsung Biologics




A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Price to Earnings analysis of Samsung Biologics

02-28-2017

 Price 164,500.00  KRW
 Earnings per share 29,375.00  KRW
 Capitalization (mn) 2,285,670  KRW
 Net income (mn) 1,938,750  KRW
 P/E ratio 5.60
 Samsung Biologics dividend
 Samsung Biologics Price to book Value
 Samsung Biologics Price to Cash-Flow
 Samsung Biologics Return on Equity
 Samsung Biologics Financial analysis

Samsung Biologics is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Samsung Biologics headquarters are in Korea, where the firm is listed.

At the time of this analysis, Samsung Biologics stocks were trading at a price of 164,500.00 KRW after climbing a 2.20% last month.

Based on the following chart, where Price Earnings Ratio is shown, Samsung Biologics has P/E of 5.60, lower than the amount offered by both companies from Korea and Pharmaceuticals and Biotechnology subsector. This low Price to earnings, might be a sing of a company undervalued or that the market expects a reduction in their earnings.Samsung Biologics financial data could confirm which is the explanation for such a low P/E ratio.

Finally, you could compare Samsung Biologics P/E with other Pharmaceuticals and Biotechnology companies or firms from Korea.

Samsung Biologics price to earnings

Next companies

Samsung Card. Korea. Financials.
Samsung Electro-Mech. Korea. Industrials.
Samsung Electronics. Korea. Consumer Goods.
Samsung Eng. Korea. Industrials.
Samsung F & M Ins. Korea. Financials.
Samsung Fine Chem. Korea. Basic Materials.

Previous companies

Samsonite Internatio. Hong-Kong. Consumer Goods.
Sampo Oyi. Finland. Financials.
Salvatore Ferragamo. Italy. Consumer Goods.
Salesforce.com. USA. Technology.
Saipem. Italy. Oil and Gas.
Sainsbury (J). UK. Consumer Services.

All rights reserved

 information advertisement legal

Dividends Ranking | Firm Report | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Part of Enciclopedia Financiera Group

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.